

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4275825

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JAMES DONALD LOUDIN	12/19/2016
MANFRED FRANKE	02/10/2017
DOUGLAS MICHAEL ACKERMANN	12/19/2016
RECEIVING PARTY DATA	
Name:	OCULEVE, INC.
Street Address:	395 OYSTER POINT BOULEVARD
Internal Address:	SUITE 501
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15367030
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 843-5962
Email:	pellison@cooley.com
Correspondent Name:	LISA A. AMII, COOLEY LLP
Address Line 1:	ATTN: IP DOCKETING DEPARTMENT
Address Line 2:	1299 PENNSYLVANIA AVENUE NW, SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	OCLV-021/04US 328562-2130
NAME OF SUBMITTER:	LISA A. AMII
SIGNATURE:	/Lisa A. Amii/
DATE SIGNED:	02/15/2017
Total Attachments: 12	
source=Executed_Assignment_in_Counterpart#page1.tif	
source=Executed_Assignment_in_Counterpart#page2.tif	

source=Executed_Assignment_in_Counterpart#page3.tif
source=Executed_Assignment_in_Counterpart#page4.tif
source=Executed_Assignment_in_Counterpart#page5.tif
source=Executed_Assignment_in_Counterpart#page6.tif
source=Executed_Assignment_in_Counterpart#page7.tif
source=Executed_Assignment_in_Counterpart#page8.tif
source=Executed_Assignment_in_Counterpart#page9.tif
source=Executed_Assignment_in_Counterpart#page10.tif
source=Executed_Assignment_in_Counterpart#page11.tif
source=Executed_Assignment_in_Counterpart#page12.tif

ASSIGNMENT

James Donald LOUDIN, residing at 203 Kilts Drive, Houston, Texas 77024; Manfred FRANKE, residing at 24015 Copper Hill Drive, Unit 7205, Valencia, California 91354; and Douglas Michael ACKERMANN, residing at 341 Crestmont Drive, San Francisco, California 94131, (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent of the United States, entitled INTRANASAL STIMULATION FOR ENHANCED RELEASE OF OCULAR MUCINS AND OTHER TEAR PROTEINS, and which is a:

- (1) provisional application
(a) to be filed herewith; or
(b) bearing Application No. **, and filed on **;
- (2) non-provisional application
(a) to be filed herewith; or
(b) bearing Application No. 15/367,030, and filed on December 1, 2016;
and/or
- (3) PCT application
(a) bearing Application No. , and filed on .

WHEREAS, Oculeve, Inc., a corporation of Delaware having its principal place of business at 395 Oyster Point Boulevard, Suite 501, South San Francisco, California 94080, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
(b) the application(s) for patent identified above;

(c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal

representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 12/19/2016 By: James Donald Loudin
James Donald LOUDIN

WITNESSED BY: _____
DATE: _____
NAME: _____

Date: _____ By: _____
Manfred FRANKE

WITNESSED BY: _____
DATE: _____
NAME: _____

Date: _____ By: _____
Douglas Michael ACKERMANN

For and on behalf of ASSIGNEE

Date: _____ By: _____
Name: _____
Title: _____
Company: **Oculeve, Inc.**

WITNESSED BY: _____
DATE: _____
NAME: _____

ASSIGNMENT

James Donald LOUDIN, residing at 203 Kilts Drive, Houston, Texas 77024; Manfred FRANKE, residing at 24015 Copper Hill Drive, Unit 7205, Valencia, California 91354; and Douglas Michael ACKERMANN, residing at 341 Crestmont Drive, San Francisco, California 94131, (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent of the United States, entitled INTRANASAL STIMULATION FOR ENHANCED RELEASE OF OCULAR MUCINS AND OTHER TEAR PROTEINS, and which is a:

- (1) provisional application
 - (a) to be filed herewith; or
 - (b) bearing Application No. **, and filed on **;

- (2) non-provisional application
 - (a) to be filed herewith; or
 - (b) bearing Application No. 15/367,030, and filed on December 1, 2016;and/or

- (3) PCT application
 - (a) bearing Application No. , and filed on .

WHEREAS, **Oculeve, Inc.**, a corporation of Delaware having its principal place of business at **395 Oyster Point Boulevard, Suite 501, South San Francisco, California 94080**, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;

RF
1/3

(c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.


The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal

representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: _____ By: _____
James Donald LOUDIN

WITNESSED BY: _____
DATE: _____
NAME: _____

Date: 2/10/2017 By: 
Manfred FRANKE

WITNESSED BY: M. Abirami
DATE: 2/10/2017
NAME: Abirami Muralidharan

Date: _____ By: _____
Douglas Michael ACKERMANN

For and on behalf of ASSIGNEE

Date: _____ By: _____
Name: _____
Title: _____
Company: **Oculeve, Inc.**

WITNESSED BY: _____
DATE: _____
NAME: _____



ASSIGNMENT

James Donald LOUDIN, residing at 203 Kilts Drive, Houston, Texas 77024; Manfred FRANKE, residing at 24015 Copper Hill Drive, Unit 7205, Valencia, California 91354; and Douglas Michael ACKERMANN, residing at 341 Crestmont Drive, San Francisco, California 94131, (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent of the United States, entitled INTRANASAL STIMULATION FOR ENHANCED RELEASE OF OCULAR MUCINS AND OTHER TEAR PROTEINS, and which is a:

- (1) provisional application
(a) to be filed herewith; or
(b) bearing Application No. **, and filed on **;
- (2) non-provisional application
(a) to be filed herewith; or
(b) bearing Application No. 15/367,030, and filed on December 1, 2016;
and/or
- (3) PCT application
(a) bearing Application No. , and filed on .

WHEREAS, Oculeve, Inc., a corporation of Delaware having its principal place of business at 395 Oyster Point Boulevard, Suite 501, South San Francisco, California 94080, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
(b) the application(s) for patent identified above;

(c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal

representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.


The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: _____ By: _____
James Donald LOUDIN

WITNESSED BY: _____
DATE: _____
NAME: _____

Date: _____ By: _____
Manfred FRANKE

WITNESSED BY: _____
DATE: _____
NAME: _____

Date: 19 Dec 2016 By: 
Douglas Michael ACKERMANN

For and on behalf of ASSIGNEE

Date: _____ By: _____
Name: _____
Title: _____
Company: **Oculeve, Inc.**

WITNESSED BY: _____
DATE: _____
NAME: _____

ASSIGNMENT

James Donald LOUDIN, residing at 203 Kilts Drive, Houston, Texas 77024; Manfred FRANKE, residing at 24015 Copper Hill Drive, Unit 7205, Valencia, California 91354; and Douglas Michael ACKERMANN, residing at 341 Crestmont Drive, San Francisco, California 94131, (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent of the United States, entitled INTRANASAL STIMULATION FOR ENHANCED RELEASE OF OCULAR MUCINS AND OTHER TEAR PROTEINS, and which is a:

- (1) provisional application
(a) to be filed herewith; or
(b) bearing Application No. **, and filed on **;
- (2) non-provisional application
(a) to be filed herewith; or
(b) bearing Application No. 15/367,030, and filed on December 1, 2016;
and/or
- (3) PCT application
(a) bearing Application No. , and filed on .

WHEREAS, Oculeve, Inc., a corporation of Delaware having its principal place of business at 395 Oyster Point Boulevard, Suite 501, South San Francisco, California 94080, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
(b) the application(s) for patent identified above;

(c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal

representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: _____ By: _____
James Donald LOUDIN


WITNESSED BY: _____
DATE: _____
NAME: _____

Date: _____ By: _____
Manfred FRANKE

WITNESSED BY: _____
DATE: _____
NAME: _____

Date: _____ By: _____
Douglas Michael ACKERMANN

For and on behalf of ASSIGNEE

Date: Dec 22, 2016 By: 
Name: Thomas Poche
Title: Vice President
Company: **Oculeve, Inc.**

WITNESSED BY: _____
DATE: _____
NAME: _____